Efficacy and diabetes risk of moderate-intensity statin plus ezetimibe versus high-intensity statin after percutaneous coronary intervention

Efficacy and diabetes risk of moderate-intensity statin plus ezetimibe versus high-intensity statin after percutaneous coronary intervention

Abstract Backgrounds High-intensity statin is recommended for patients undergoing percutaneous coronary intervention (PCI), and ezetimibe is recommended to be added in patients not achieving low-density lipoprotein cholesterol (LDL-C) targets. Moderate-intensity statin plus ezetimibe can reduce LDL-...

Full description

Saved in:
Bibliographic Details
Main Authors: Eun Ho Choo, Donggyu Moon, Ik Jun Choi, Sungmin Lim, Jungkuk Lee, Dongwoo Kang, Byung-Hee Hwang, Chan Joon Kim, Jong-Min Lee, Ki-Dong Yoo, Doo Soo Jeon, Kiyuk Chang
Format: Article
Language:English
Published: BMC 2024-11-01
Series:Cardiovascular Diabetology
Subjects:
Coronary artery disease
Dyslipidemia
Ezetimibe
Statin
Percutaneous coronary intervention
Online Access:https://doi.org/10.1186/s12933-024-02498-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12933-024-02498-3

Similar Items